Skip to main content

Table 4 Summary of treatment-emergent adverse events (regardless of causality) in either dosing subgroup

From: Sensitivity to angiotensin II dose in patients with vasodilatory shock: a prespecified analysis of the ATHOS-3 trial

  Angiotensin II > 5 ng kg−1 min−1 (n = 84) Angiotensin II ≤ 5 ng kg−1 min−1 (n = 79)
Any grade, n (%) 76 (90.5) 66 (83.5)
Grade 3/4, n (%) 64 (76.2) 43 (54.4)
Serious adverse events, n (%) 64 (76.2) 35 (44.3)
Adverse events resulting in discontinuation, n (%) 19 (22.6) 4 (5.1)
Fatal adverse events, n (%) 0 1 (1.3)